Abstract: An integrated fluorescence detector for detecting fluorescent particles is described. An example integrated fluorescence detector comprises a substrate, the substrate comprising an integrated detection element for detecting fluorescence radiation from fluorescent particles upon excitation of the particles with incident excitation radiation. The integrated fluorescence detector also comprises a sensing layer adapted for accommodating fluorescent particles to be sensed. The integrated fluorescence detector further comprises a photonics crystal layer arranged in between the sensing layer and the substrate, the photonics crystal layer comprising an absorption material designed such that the photonics crystal layer is configured for diffracting incident excitation radiation into a lateral direction in which the photonics crystal layer extends for incident excitation radiation having a wavelength within at least 10 nm of the predetermined excitation wavelength.

Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

Abstract: A capsule for use in a brewing device is provided, comprising a body part, which defines a cavity and which has a flange, a lid which is attached to the flange and tea material enclosed within the capsule, characterized in that the shape of the flange is defined by two intersecting circular arcs when viewed from above. A brewing device which comprises a capsule holder for receiving the capsule is also provided, the capsule holder comprising a sidewall which is circular when viewed from above and which has an upper rim, a shelf on at least part of the inside of the sidewall, a filter and an openable and closable passage on the opposite side of the filter from the upper rim. A method of preparing a tea-based beverage in the brewing device using the capsule is also provided.

Abstract: The present invention permits RMS traveltime error in a seismic data acquisition to be minimized. Field measurements of source and receiver coordinates, speed of sound in water as a function of depth and time, receiver timing, and clock drift are first collected. The seismic data is then examined to measure travel time from each source to each reciever. A model travel time can then be computed based on the field measurements. By iteratively perturbing at least one of the field measured data using a look-up table and calculating the travel time after each perturbation until an acceptable RMS error has been achieved, conditioned seismic data that takes into account the dynamic nature of the water column will provide the basis for creating an accurate seismic map that is unaffected by the changing water conditions.

Abstract: Fat powder comprising hardstock fat co-crystallized with at least one emulsifier, wherein said emulsifier has a HLB value of 8 or lower and comprises at least 40 wt. %, based on the total weight of the emulsifier, of mono- and/or diglycerides having saturated fatty acid with a carbon chain length of at least 12, and wherein said hardstock fat is characterized by the following solid fat profile: N10 from 95 to 30; N20 of at least 15; N35 of at most 35; and wherein the weight ratio of said hardstock fat to said emulsifier is from 1:0.010 to 1:0.5. The invention further relates to a process wherein said fat powder is used for the manufacture of water-in-oil emulsions. The invention further relates to water-in-oil emulsions having an improved stability.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

Abstract: A plasmonic structure comprises a substrate and an electro conductor provided in or on the substrate. The electro conductor comprises a first part configured to provide a first series of plasmon resonance modes (for incident radiation of a first wavelength) and a second part configured to provide a second series of plasmon resonance modes (for incident radiation of a second wavelength). The first and second parts are functionally connected in a linkage region, wherein the electro conductor is shaped such as to form a capacitive gap. The electro conductor is further configured to direct radiation incident on the plasmonic structure of the first wavelength predominantly toward a first direction and to direct radiation incident on the plasmonic structure of the second wavelength predominantly toward a second direction, in which the first direction and the second direction are separated by an angle of at least 60°.

Abstract: The present invention is concerned with novel 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles having formula (I) stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

Abstract: A conversion device may receive a first message in a Telelocator Alphanumeric Protocol (TAP) format. The first message may include information that identifies a user device as an intended recipient of the first message. The first message may not be transmissible over a wireless connection. The conversion device may convert the first message into a second message in a first format capable of being transmitted over the wireless connection. The second message may include information that identifies the user device. The conversion device may provide the second message, using the wireless connection, to a messaging device. The wireless message may cause the messaging device to convert the second message into a third message in a second format that is capable of being delivered to the identified user device. The wireless message may further cause the messaging device to provide the third message to the user device.

Abstract: This invention provides promoter sequences that are useful for modulating transcription of a desired polynucleotide and/or in the construction of recombinant genes for plant transformation to enable expression of foreign or endogenous coding sequences in plants. The promoters are functional in a both monocotyledonous and dicotyledonous plant species and are active in a wide range of vegetative or generative plant organs. The invention also provides a polynucleotide construct comprising a promoter of the invention operably linked to a foreign or endogenous polynucleotide encoding a protein of interest or a transcript capable of modulating expression of a target gene. The invention is further concerned with transformed plant cells, as well as differentiated plants, plant parts, plant tissues or plant seeds containing the construct.

Abstract: Embodiments of the invention pertain to a method for producing a spectacle lens with optimal correction across the entire lens that take the patient's complete measured wavefront into account. Specific embodiments also consider one or more additional factors such as vertex distance, intermediate power, add power, segmental fitting height, pantoscopic tilt, and use conditions. The lens wavefront can be achieved by optimizing a corrected wavefront, where the corrected wavefront is the effect of the patient's measured wavefront and/or the lens wavefront. The optimization of the corrected wavefront can involve representing the measured wavefront and/or the lens wavefront on a grid. In an exemplary embodiment, the grid can lie in a plane. During the optimization, a subset of the grid can be used for the representation of the measured wavefront at a point on the grid so that the portions of the measured wavefront that contribute to the corrected wavefront at that point on the grid are taken into account.

Abstract: A tractor assembly includes a connection unit which is connected between the tractor and the wheel chair. The connection unit includes a fixing member, a top link unit, a bottom link unit and a swing rod so as to form a four-link mechanism. The connection unit includes an engaging unit with an engaging section, and a position unit. The top link unit has a reception hole and the positioning unit has a push rod. When the push rod is located at the first position, the reception hole is closed. When the push rod is located at the second position, the push rod is retracted and the reception hole is exposed. The bottom link unit is pivoted about one end of the swing rod to move the other end of the swing rod to the position of the reception hole, the engaging section is inserted into the reception hole.

Abstract: The track assembly for a vehicle seat, comprising two parallel tracks, an electric motor, flexible connections connecting the electric motor to the track drive mechanisms and motor support members provided with guides in which the flexible connections are held.

Abstract: An implantable device is provided for controlling hemorrhage in a body cavity, comprising an expandable balloon and a conduit for supplying a physiologically compatible fluid to inflate the balloon. When the balloon tamponade device is implanted or inserted into the body cavity, it is inflated with a physiologically suitable fluid, so that the balloon generally conforms to the body cavity and exerts compressive force against the walls, tissues or structures of the body cavity to control hemorrhage. The balloon may have a deforming means to limit expansion of the balloon in a direction to facilitate expansion of the balloon in another direction. The device may have additional tubes within the conduit, or a plurality of separate lumens within the conduit or tubes to allow drainage and irrigation to the body cavity. There is also provided a cuff for attachment of an external traction to the balloon tamponade, to facilitate the compressive effect of the device.

Abstract: A device is provided for loading a roll, including: a housing including a chamber defining an open cavity; and a roll support. The roll is rotatably mounted in the cavity.

Abstract: An assembly provides a proportioned gas flow and includes a device that provides a pressurized flow of said gas, a release unit that releases the proportioned gas flow, and a chamber having an inlet fluidically connected to the device and an outlet fluidically connected to the release unit. The assembly further includes an admission valve inserted between the inlet of the chamber and the device, a metering valve inserted between the outlet of the chamber and the release unit, and a computer programmed to control the admission valve and the metering valve to provide a proportioned gas flow to the release unit. The assembly further comprises a calibrated orifice inserted between the outlet of the chamber and the release unit.